« Return to News | R&D Trends

Cenix, SYGNIS sign RNAi research agreement

Thursday, November 17, 2011 02:02 PM

Cenix BioScience, a discovery-stage contract research provider and technology developer, has signed a research agreement with SYGNIS Bioscience, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.

Under the research agreement's first assignment to advance the SYGNIS
KIBRA project, Cenix will apply its long-standing expertise in combining
high content screening with gene silencing analyses in cultured human cells, to establish and optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system.

Using such assays, Cenix will conduct target validation to prioritize
novel therapeutic drug target candidates, thereby accelerating and enriching the SYGNIS drug development pipeline.
 
"We are delighted to enter into this new relationship with SYGNIS," noted Dr. Christophe Echeverri, CEO/CSO of Cenix. "This project, and the many others like it now ongoing here and throughout the industry, continue to confirm the unparalleled power of RNAi-based experimentation for not only discovering but also validating and de-risking new candidate drug targets."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.